It's a welcome sight for shareholders who haven't had much to rejoice about lately. What a difference a day can make. Until Aug. 8, shares of Doximity (DOCS 0.69%), a healthcare-focused networking platform, were in the red for the year. However, on Aug. 9, the company's stock skyrocketed by more than 33%, making its year-to-date performance better than that of the broader market. As investors might guess, Doximity's gains had something to do with its latest quarterly report, but even after this jump, shares ...

Morsa Images Pondering the issue of sustainable growth Earlier this month, Doximity, whose shares had been languishing in investor purgatory for most of 2024 reported its results for fiscal Q1 2025. The results were significantly better than had been anticipated with revenues of $127 million compared to the prior forecast of $120 million, and adjusted EBITDA of $66 million compared to a prior forecast of $56 million. Year over year revenue growth was 17% while the adjusted EBITDA rose by 42% and the adjuste ...

Doximity Today DOCS Doximity $36.21 +0.18 (+0.50%) 52-Week Range $19.71 ▼ $37.25 P/E Ratio 50.29 Price Target $31.27 Add to Watchlist Doximity Inc. NASDAQ: DOCS is a digital professional medical networking platform that is a cross between LinkedIn and Meta Platforms Inc. NASDAQ: META Facebook. The platform enables physicians to connect with their colleagues to collaborate on patient treatments and research. It also provides the latest medical news and research and provides access to various career tools. Do ...

Solskin Introduction & Investment Thesis I last wrote about Doximity (NYSE:DOCS) in April, where I rated the stock a "hold." Although I stated that the stock has a potential upside of at least 29% from its levels back then, I believed that investors would be weary until the management could reignite the growth story. Since then, the stock has climbed 45% as it reported a strong Q1 FY25 earnings report, where revenue and Adjusted EBITDA grew 17% and 41% YoY, respectively, beating estimates. Simultaneously, t ...

Core Viewpoint - Doximity's strong fiscal first-quarter earnings report led to a significant increase in its stock price, reflecting positive investor sentiment and confidence in the company's growth potential [1]. Financial Performance - Revenue grew by 17% to $126.7 million for the period ending June 30, surpassing the consensus estimate of $119.9 million [2]. - Adjusted EBITDA increased by 42% to $65.9 million, resulting in an EBITDA margin exceeding 50% [2]. - Adjusted earnings per share rose from $0.19 to $0.28, exceeding expectations of $0.22 [2]. User Engagement - The company reported a record engagement with 590,000 providers utilizing Doximity's tools, including artificial intelligence, telehealth, and scheduling [3]. Future Guidance - For the fiscal second quarter, Doximity expects revenue between $126.5 million and $127.5 million, indicating a 12% growth at the midpoint, which is better than the estimate of $124 million [4]. - The company anticipates adjusted EBITDA of $62.5 million to $63.5 million for the same period [4]. - For the full year, revenue is projected to be between $514 million and $523 million, reflecting a more modest growth of 9% at the midpoint, ahead of the estimate of $512.2 million [5]. - Adjusted EBITDA for the full year is expected to range from $248.5 million to $257.5 million [5]. Market Position - Despite being down from its pandemic peak, Doximity's high margins indicate its operational strength [6]. - Continued growth in user base and engagement is crucial for sustaining stock price momentum [6].

Doximity (NYSE:DOCS) stock is rising higher on Friday following the release of the medical cloud-based digital platform company's earnings report for its fiscal first quarter of 2025. That earnings report starts off strong with adjusted EPS of 28 cents per share. This is better than the 23 cents per share Wall Street was expecting. It's also an improvement over the 19 cents per share reported in the same period of the year prior. Adding to this is revenue of $126.7 million in fiscal Q1. That's another beat ...

Financial Data and Key Metrics Changes - Doximity reported Q1 2025 revenue of $127 million, reflecting a 17% year-on-year growth and exceeding the high end of guidance by 5% [4][5] - Adjusted EBITDA margin was 52%, amounting to $66 million, which is 18% above the high end of guidance, with adjusted EBITDA growing 42% year-on-year [5][11] - Non-GAAP gross margin increased to 92% from 90% in the prior year [11] Business Line Data and Key Metrics Changes - The top 20 clients grew revenue by 21% on a trailing 12-month basis, indicating strong demand from major pharmaceutical manufacturers [5][11] - Doximity ended the quarter with 102 customers contributing at least $500,000 each in subscription-based revenue, a 16% increase from the previous year [11] Market Data and Key Metrics Changes - Unique active prescribers using Doximity's tools reached a record 590,000, with significant growth in daily active users [6][7] - The company reported that its new products, particularly in point of care and formulary, saw sales increase by over 70% year-on-year [14] Company Strategy and Development Direction - Doximity is focused on leveraging AI to enhance its offerings, including the launch of Doximity GPT, which has seen over 1.5 million prompts completed [7][8] - The new client portal is designed to provide real-time insights and actionable recommendations, enhancing client engagement and driving upsell opportunities [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's competitive position and ability to gain market share, despite acknowledging ongoing macroeconomic uncertainties [15] - For Q2 2025, Doximity expects revenue in the range of $126.5 million to $127.5 million, representing a 12% growth at the midpoint [13] Other Important Information - Free cash flow for Q1 was $39.5 million, a decrease of 29% year-on-year, primarily due to the timing of tax payments [12] - The company repurchased $48.2 million worth of shares, reducing fully diluted shares outstanding by 6% since Q1 of last year [12] Q&A Session Summary Question: Updated stance on pharma budget growth for the full year - Management believes overall budget growth for pharma customers remains at roughly 5% to 7%, but clients are more comfortable deploying dollars earlier in the upsell cycle due to the strong product portfolio [16] Question: Driving factors behind record engagement on the platform - Daily active users grew significantly as Doximity becomes a key tool for doctors' mobile medical workflows, with more physicians working remotely [18] Question: Trends in client portal usage - Clients are using the portal for real-time insights, which has led to faster growth among brands with access compared to the overall pharma business [21] Question: Variability in company growth rates - Management noted that quarterly variations in revenue are expected due to the timing of upsells and product launches, emphasizing the importance of annual performance [22] Question: Performance of the curative business segment - The curative business saw strong quarter-over-quarter growth, with a focus on leveraging AI for recruiting [55]

Doximity (DOCS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 27.27%. A quarter ago, it was expected that this medical social networking site would post earnings of $0.20 per share when it actually produced earnings of $0.25, delivering a surprise of 25%. Over the last four quarters ...

Table of Contents Title of each class Trading Symbol(s) Name of exchange on which registered DOCS The New York Stock Exchange Class A common stock, $0.001 par value per share UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPO ...

Exhibit 99.1 Doximity Announces Fiscal 2025 First Quarter Financial Results Total revenues of $126.7 million, up 17% year-over-year Net income growth of 46% and adjusted EBITDA growth of 42% year-over-year SAN FRANCISCO, Calif., August 8, 2024 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 first quarter ended June 30, 2024. "We were pleased to deliver strong profits and record engagement last quarter, as we beat on both ...